30.01
0.15 (0.50%)
| Previous Close | 29.86 |
| Open | 29.86 |
| Volume | 1,151,597 |
| Avg. Volume (3M) | 1,264,075 |
| Market Cap | 1,676,916,480 |
| Price / Sales | 5.81 |
| Price / Book | 4.66 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.75 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (Morgan Stanley, 69.94%) | Buy |
| 51.00 (Wells Fargo, 69.94%) | Buy | |
| Median | 50.00 (66.61%) | |
| Low | 50.00 (Piper Sandler, 66.61%) | Buy |
| 50.00 (TD Cowen, 66.61%) | Buy | |
| 50.00 (Truist Securities, 66.61%) | Buy | |
| Average | 50.40 (67.94%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 31.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 51.00 (69.94%) | Buy | 29.53 |
| Piper Sandler | 05 Nov 2025 | 50.00 (66.61%) | Buy | 31.61 |
| TD Cowen | 05 Nov 2025 | 50.00 (66.61%) | Buy | 31.61 |
| Wells Fargo | 05 Nov 2025 | 51.00 (69.94%) | Buy | 31.61 |
| Truist Securities | 15 Oct 2025 | 50.00 (66.61%) | Buy | 33.76 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 |
| 04 Nov 2025 | Announcement | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance |
| 15 Oct 2025 | Announcement | PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |